Rhythm Pharmaceuticals
NASDAQ · RYTM·Boston, MA·Mid-cap·Approved
Commercial-stage biopharma focused on rare neuroendocrine diseases. IMCIVREE (setmelanotide) is approved for genetic obesities including BBS, POMC and LEPR deficiencies. Pipeline includes bivamelagon (oral MC4R agonist) and RM-718 (next-gen weekly).
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Rhythm Corporate Presentation April 2026 | Corporate overview | April 15, 2026 | 50 |